Spinocerebellar ataxia type 1 (SCA1) is one of several neurodegenerative diseases caused by expansion of a polyglutamine tract in the disease protein, in this case, ATAXIN-1 (ATXN1). A key question in the field is whether neurotoxicity is mediated by aberrant, novel interactions with the expanded protein or whether its wild-type functions are augmented to a deleterious degree. We examined soluble protein complexes from mouse cerebellum and found that the majority of wild-type and expanded ATXN1 assembles into large stable complexes containing the transcriptional repressor Capicua. ATXN1 directly binds Capicua and modulates Capicua repressor activity in Drosophila and mammalian cells, and its loss decreases the steady-state level of Capicua. Interestingly, the S776A mutation, which abrogates the neurotoxicity of expanded ATXN1, substantially reduces the association of mutant ATXN1 with Capicua in vivo. These data provide insight into the function of ATXN1 and suggest that SCA1 neuropathology depends on native, not novel, protein interactions.
INTRODUCTION
SCA1 (Spinocerebellar ataxia type 1) is one of nine unrelated genes in which expansion of a glutamine-encoding triplet repeat causes a dominantly inherited neurodegenerative disease. Despite broad expression of polyglutamine proteins, distinct subsets of neurons are vulnerable in each disease. Genetic studies have shown that expansion of the polyglutamine tract confers a toxic gain of function (Duyao et al., 1995; Ikeda et al., 2005; Matilla et al., 1998; Matsumoto et al., 2005; Nasir et al., 1995; Zeitlin et al., 1995) . The nature of this gain of function has, however, remained mysterious. While it is clear that polyglutamine tract expansion alters the conformation of soluble mutant proteins and decreases protein solubility leading to aggregation (Ross and Poirier, 2004) , there is considerable debate as to the biophysical and biochemical state of the disease protein that renders it neurotoxic and the mechanism that leads to selective neuronal vulnerability in each of these disorders.
Emerging data reveal that neurotoxicity is modulated by the context of the polyglutamine expansion. For example, the S776A mutation of polyglutamine-expanded ATAXIN-1 (ATXN1) prevents the ataxia and neurodegeneration caused by expression of the SCA1 disease protein in mouse Purkinje cells (Emamian et al., 2003) . Likewise, in Huntington disease, phosphorylation, SUMO modification, or mutation of the Caspase-6 cleavage site modulate the neurotoxicity of mutant Huntingtin (Graham et al., 2006; Luo et al., 2005; Pardo et al., 2006; Rangone et al., 2004; Steffan et al., 2004; Warby et al., 2005) . Full-length, but not truncated, polyglutamine-expanded androgen receptor reproduces the sex-specific neuropathology of SBMA (Chevalier-Larsen et al., 2004; Katsuno et al., 2002; McManamny et al., 2002) . The discovery that the AXH domain of ATXN1 mediates SCA1 neurotoxicity further emphasized the importance of cis-acting domains in pathogenesis and the relationship between such domains and the polyglutamine tract (Tsuda et al., 2005) . Lastly, studies from Huntington and SCA3 models have revealed a genetic interaction between the wildtype proteins and their polyglutamine-expanded counterparts (Cattaneo et al., 2005; Van Raamsdonk et al., 2005; Warrick et al., 2005; Zuccato et al., 2003) . These observations suggest a relationship between the selective neurotoxic properties of the polyglutamine-expanded protein and the normal functions of the wild-type protein.
Aberrant protein interactions are thought to mediate neurotoxicity in polyglutamine diseases (Gatchel and Zoghbi, 2005; Harjes and Wanker, 2003; Li and Li, 2004; MacDonald, 2003) . Polyglutamine expansion alters the interactions of Huntingtin with HAP1/p150
Glued /dynein complexes, as well as numerous transcription factors, leading to their functional impairment (Chen-Plotkin et al., 2006; Dunah et al., 2002; Gauthier et al., 2004; Kegel et al., 2002; Li et al., 2002; Schaffar et al., 2004; Zhai et al., 2005; Zuccato et al., 2003) . Other examples of altered protein-protein interactions include Ataxin-7 with CRX and the STAGA/TFTC complexes and Ataxin-3 with components of the ubiquitin proteasome system (Chen et al., 2004; Doss-Pepe et al., 2003; Helmlinger et al., 2006; McMahon et al., 2005; Palhan et al., 2005; Strom et al., 2005; Warrick et al., 2005) . Nevertheless, it is unknown if neurotoxicity of the mutant proteins occurs through associations with these native protein complexes, loss of these associations, or aberrant interactions and novel complexes formed by misfolded or aggregating disease protein.
To test the hypothesis that polyglutamine expansion mediates pathology by modulating the native protein interactions of the disease protein, we sought to characterize the endogenous ATXN1 protein complexes in mouse cerebellum and identify ATXN1-associated proteins by biochemical copurification from stable cell lines. We report that ATXN1 isolated from mouse cerebellum predominantly associates into large complexes containing the mammalian homolog of Drosophila Capicua (CIC), a transcriptional repressor containing a Sox-like high mobility group (HMG) box. Both major isoforms of CIC (CIC-L and CIC-S) are subunits of these complexes. We demonstrate that expression of polyglutamine-expanded ATXN1 alters the repressor activity of CIC, establishing a functional link between the two proteins. Finally, we provide evidence that SCA1 neuropathology depends on incorporation of polyglutamine-expanded ATXN1 into its native CIC-containing complexes.
RESULTS

ATXN1 and CIC Associate into Large Protein Complexes
To identify the major ATXN1 protein complexes in vivo, we examined soluble ATXN1-associated complexes in wildtype mouse cerebellum using gel-filtration and ion exchange chromatography. Gel filtration revealed that the majority of endogenous wild-type ATXN1 ($75%) elutes as large protein complexes (estimated size $1.8 MDa) (Figures 1A and 1B) . Only about 25% of ATXN1 elutes as smaller protein complexes (observed as a shoulder on the larger complexes elution profile, estimated size $300 kDa) ( Figure 1B, right panel) .
To identify proteins that interact with ATXN1 in its native complexes, we purified ATXN1-associated proteins by tandem affinity purification (TAP) (Rigaut et al., 1999) and mass spectrometry ( Figure S1 ). We found two novel interacting proteins with apparent molecular masses of $160 kDa and $250 kDa, both corresponding to the human homolog of Drosophila Capicua (Cic). Northern blot analysis of mouse brain RNA for Cic identified two major transcripts ( Figure S5A ) corresponding to two Cic mRNA transcripts predicted to encode proteins of 258 kDa for CIC-L and 164 kDa for CIC-S ( Figure S2A ). We also identified these alternatively spliced CIC mRNA transcripts for both human and Drosophila (Figures S2A and S2B) . To detect the endogenous CIC protein, we generated antisera against the common C-terminal region of the mouse CIC isoforms ( Figure S3A ). This antibody specifically recognized CIC-L and CIC-S from mouse cerebellar and HeLa cell extracts (Figures 1 and S3B ).
To determine whether CIC is a stable ATXN1-interacting partner, we analyzed the elution profile of CIC by gel-filtration chromatography. We observed that CIC-S and CIC-L coeluted with the large ATXN1 protein complexes ( Figures  1A and 1B) . Quantification of the relative elution profiles of CIC and ATXN1 using 1 ml fractions, which allows the entire profile to be analyzed on a single gel, revealed a near perfect match between the elution profiles of CIC and the large ATXN1 complexes ( Figure 1B) .
If CIC and ATXN1 are components of the same protein complexes, loss of ATXN1 will alter the elution profiles of CIC. Indeed, we found that elution of the CIC isoforms is shifted toward later fractions in cerebellar extracts from Sca1 null mice ( Figure S4 ). Furthermore, we observed a strict cofractionation of ATXN1 with the CIC isoforms using anion exchange chromatography ( Figure 1C ). Although no significant population of ATXN1 fractionated independently of CIC, we did detect low levels of ATXN1 in the flow-through fractions in the absence of detectable CIC (data not shown), suggesting the smaller ATXN1 complexes have minimal binding to the column matrix.
In sum, the nearly identical elution patterns of the large ATXN1 complexes with CIC-L and CIC-S, and the shift of the CIC profiles in the absence of ATXN1, suggest that the majority of endogenous CIC in the mouse cerebellum stably associates into ATXN1-CIC protein complexes. Also, the smaller ATXN1 protein complexes likely do not contain CIC.
ATXN1 and CIC Interact In Vivo and Colocalize in the Adult Mouse Brain
To determine whether ATXN1 and CIC interact in the tissue most vulnerable in SCA1, we performed coimmunoprecipitation (coIP) of cerebellar extracts from wild-type and Sca1 null mice using anti-ATXN1 antibody (11NQ). The anti-ATXN1 antibody specifically immunoprecipitated both CIC isoforms from cerebellar extracts of wild-type but not Sca1 null mice, indicating that CIC and ATXN1 interact in vivo ( Figure 2A ; input and loading controls for this coIP are in Figure 3A ). This is in agreement with our recent work, in which we identified CIC as a binding partner of ATXN1 in an unbiased yeast two-hybrid screen (Lim et al., 2006) .
Having established the ATXN1-CIC interaction, we compared their expression patterns in mouse brain. Northern blot analysis showed that the Cic isoforms are highly (B) Representative westerns of 1.0 ml gel-filtration fractions of wild-type cerebellar extracts analyzed for CIC and ATXN1. Right panel illustrates the elution profiles for each protein plotted as the average percent protein (± standard error) in each fraction from four independent extracts. The total signal in each fraction (measured by densitometry) is divided by the total signal of that protein in all the fractions to determine the percentages shown in the panel. The column void volume (V o ), gel-filtration standards thyroglobulin (669 kDa) and ADH (150 kDa), and elution volume (ml) of each collected fraction are indicated. (C) Representative westerns of monoQ fractions from wild-type cerebellar extracts analyzed for CIC and ATXN1; the approximate eluting NaCl concentration of selected fractions and elution volume (ml) of each collected fraction are indicated. expressed in the cerebellum and olfactory bulb (Figure S5A, upper panel) . In situ hybridization of adult mouse brain for Cic and Sca1 revealed strikingly similar expression patterns, with high expression in Purkinje cells and in the hippocampus (Figures S5B-S5I ). Immunohistochemistry for CIC and ATXN1 also displayed matching protein expression patterns in most brain regions (data not shown). Importantly, both proteins are highly expressed in the nuclei of the Purkinje cells, where polyglutamineexpanded ATXN1 does the most damage ( Figure 2B ).
To look for interdependence between CIC and ATXN1, we examined CIC protein levels in Sca1 null mice. We found that both CIC isoforms had significantly reduced levels in Sca1 null mouse cerebellum (Figures 2C and 2D) and cerebrum (data not shown). As the mRNA levels of the Cic isoforms are unaltered in Sca1 null mice, the dependency of CIC on ATXN1 is posttranscriptional (Figure 2E ). Thus, CIC is less stable in the absence of ATXN1 in vivo.
The Majority of CIC Associates with ATXN1 In Vivo
To assess the degree of CIC association with ATXN1 in vivo, we immunoprecipitated ATXN1 from cerebellar extracts and measured the codepletion of CIC from the post-IP supernatants. Both CIC isoforms were substantially depleted following ATXN1 immunodepletion, demonstrating that the majority of endogenous CIC associates with ATXN1 ( Figure 3A ). In contrast, the levels of neither Gapdh (data not shown) or AKT ( Figure 3A ), an ATXN1 kinase thought to interact transiently with ATXN1 (Chen et al., 2003) , are decreased by ATXN1 immunodepletion. Averaging data from independent experiments, we observed that when an average of 72% of ATXN1 is immunodepleted, an average of 62% of CIC-L and 56% of CIC-S are codepleted from the cerebellar extracts. We therefore estimate that $80% of endogenous CIC associates with ATXN1 ( Figure 3B ). The depleted CIC isoforms are found in the pellet of the immunoprecipitate (see for example Figure 2A ).
A Conserved Domain of CIC Interacts with the AXH Domain of ATXN1
To establish whether CIC also interacts with mutant forms of ATXN1, we performed immunoprecipitation on lysates from HeLa cells transiently transfected with variants of FLAG-tagged ATXN1 containing 2Q, 82Q, or 82Q with a S776A mutation (which abolishes the interaction of ATXN1 with 14-3-3) or 2Q with a deletion of the AXH domain. We found that both endogenous CIC isoforms coimmunoprecipitated with each of these ATXN1 variants, except the one lacking the AXH domain ( Figure 3C ). We conclude that the ATXN1-CIC interaction requires the AXH domain and is independent of 14-3-3 binding.
To identify the domains responsible for interaction between the two proteins, we performed yeast two-hybrid interaction assays using a series of ATXN1 and CIC deletion constructs. We found that two N-terminal fragments of CIC-S (amino acids 1-300 and 1-205) interact with the C-terminal half of ATXN1 and that the AXH domain of ATXN1 is sufficient for its interaction with CIC (Figure 3D ). To further map the ATXN1 binding domain of CIC, we generated serial deletions at the N terminus of mouse CIC-S for pull-down assays with GST-tagged full-length wild-type ATXN1 ( Figures S6A and S6B ). We The coIP was performed with anti-ATXN1 antibody (11NQ) and immunoblotted with anti-CIC antibody. Preimmune serum served as the negative control (input and loading controls are in Figure 3A ). narrowed the interaction region to 31 amino acids (amino acids 16-46) of CIC-S ( Figure S6C ). Comparison of this 31-amino acid sequence across species revealed a conserved stretch of eight amino acids present in both CIC-S and CIC-L isoforms with the consensus sequence Figure 3E ). We then confirmed in vitro that human ATXN1 binds to Drosophila Cic through the consensus eight amino acids ( Figure S6D ). ATXN1 and CIC thus appear to be in vivo binding partners that interact directly through evolutionarily conserved domains. (Watase et al., 2002) . As previously reported, the levels of soluble expanded protein are significantly lower than wild-type ATXN1 levels in these animals, although expression of the mutant allele is identical to the wild-type allele (Watase et al., 2002) . Gel-filtration chromatography of extracts from early symptomatic animals (10-15 weeks of age) revealed that soluble ATXN1[154Q] and wild-type ATXN1 (expressed from the untargeted allele) eluted into the same fractions as ATXN1 from wild-type extracts ( Figure 4A ). The elution profile of CIC from Sca1
154Q/+ mice is indistinguishable from that seen in wild-type animals ( Figure 4A ). A subtle change in the elution profile of the smaller ATXN1 complexes (elution fractions from 13 ml to 16 ml) was observed in the mutant animals: both ATXN1[154Q] and wild-type ATXN1 showed a relative loss from elution fractions at 14 ml and beyond, with a corresponding increase in elution fractions at 13 ml and 13.5 ml (estimated size $500 kDa) compared to wild-type animals (compare Figure 1A to 4A). The basis for this change is unclear at present, but it could represent an alternate conformation of the smaller ATXN1 protein complexes coupled with the slight increase of molecular weight due to polyglutamine expansion. The similar elution patterns of wild-type and expanded ATXN1 by gel-filtration chromatography suggest that polyglutamine expansion does not prevent the incorporation of ATXN1 into its normal endogenous protein complexes. To confirm that polyglutamine-expanded ATXN1 incorporates into similar complexes as wild-type ATXN1, we analyzed cerebellar extracts from Sca1 154Q/+ animals by anion-exchange chromatography. We found that ATXN1[154Q] coelutes with wild-type ATXN1 and with both CIC isoforms ( Figure 4B ). The elution profiles of ATXN1, CIC-L, and CIC-S in extracts by anion-exchange chromatography are quite broad; this argues against a single complex of uniform structure and suggests that the ATXN1-CIC protein complexes adopt multiple conformational or compositional states separable by differences in their charge ( Figures 1C and 4B ).
The S776A Mutation Reduces Incorporation of Mutant ATXN1 into the Large ATXN1-CIC Complexes We previously showed that mutating serine 776 of ATXN1 to alanine (S776A) dramatically suppresses the neurotoxicity of the polyglutamine-expanded protein in Purkinje cells (Emamian et al., 2003) . This mutation causes loss of interaction with the chaperone protein 14-3-3 (Chen et al., 2003 (Burright et al., 1995; Emamian et al., 2003) . We analyzed cerebellar extracts from Tg-SCA1[82Q] mice by gel filtration and found that ATXN1[82Q] associates into both large and small protein complexes ( Figures 4C and 4E) . However, cerebellar extracts from Tg-SCA1[82Q]S776A showed a specific loss of ATXN1[82Q]S776A from the large protein complexes, whereas wild-type ATXN1 had an elution profile similar to wild-type extracts ( Figures 4D and 4E ). The normal elution pattern of endogenous wild-type ATXN1 suggested that the elution profile of CIC would be similar in Tg-SCA1[82Q]S776A and wild-type animals, and this indeed was the case. Failure of ATXN1[82Q]S776A to incorporate into the large ATXN1-CIC complexes is not due to a general inability of the S776A mutant protein to physically bind CIC, as both endogenous CIC isoforms from HeLa cells can be coimmunoprecipitated with ATXN1, independent of polyglutamine expansion and/or the S776A mutation ( Figure 3C ). This suggests that the S776 residue of ATXN1 plays a critical role in regulating ATXN1-CIC complex formation in Purkinje cells.
Human Mutant ATXN1 Blocks Cic Function in Drosophila
The finding that loss of polyglutamine-expanded ATXN1 from its large native complexes correlates with a lack of neuronal dysfunction in Tg-SCA1[82Q]S776A suggests that mutant ATXN1 might cause toxicity by altering the function of its native complexes. We hypothesized that polyglutamine-expanded ATXN1 affects the function of its native complex by interfering with the function of CIC. To explore this possibility we turned to Drosophila, where the function of Cic has been investigated in vivo.
We performed genetic interaction studies to determine whether Cic can modify ATXN1 phenotypes and whether ATXN1 interferes with the repressor function of Cic in vivo. We previously showed that expression of human SCA1 [82Q] in the Drosophila eye causes a degenerative phenotype (Fernandez-Funez et al., 2000) . To test whether Drosophila cic modifies the SCA1[82Q] eye phenotype, we generated transgenic flies expressing Drosophila cic. mutant flies, an EMS-induced null allele (Roch et al., 2002) . At room temperature, SCA1[82Q] flies show milder ommatidial disorganization due to decreased expression of the disease protein ( Figure 5E ). But loss of one functional allele of cic, which by itself causes no eye phenotype, worsened ommatidial disorganization in these SCA1 [82Q] flies (compare Figure 5E to 5F). In Drosophila, Cic functions as a transcriptional regulator important for various developmental processes (Atkey et al., 2006; Jimenez et al., 2000; Roch et al., 2002) . In the developing wing, Cic represses several wing-vein specific genes, argos (aos), ventral veinless (vvl), and decapentaplegic (dpp), and cic mutants develop ectopic and thickened wing veins (Roch et al., 2002) . This provided an excellent opportunity to study the effects of ATXN1 on Cic's endogenous repressor function, because expression of human SCA1 [82Q] and Drosophila Atxn1 in the wing also causes wing-vein phenotypes (Tsuda et al., 2005) .
Using a wing-pouch specific driver (C5-GAL4) to express SCA1[82Q], we observed smaller wings with a thicker L3 vein, a missing posterior crossvein, and ectopic vein formation ( Figure 6A ). These phenotypes were more prominent at the posterior part of the wing, where the expression of the transgene was highest ( Figure 6N ). The higher expression of SCA1 [82Q] in males (due to insertion of the transgene on the X chromosome) produced atrophic wings ( Figure 6E ). In the wild-type pupal wing at 36 hr after puparium formation (APF), the expression of aos was confined to the vein region as shown by LacZ staining ( Figure 6L ). In contrast, aos expression was derepressed in flies expressing SCA1 [82Q] in the wing pouch under the control of the C5-GAL4 driver ( Figure 6M ). Furthermore, expansion of the aos expression domain correlated with the expression of SCA1[82Q] ( Figure 6N ). These data indicate that overexpression of ATXN1[82Q] impairs Cic function, probably through direct protein-protein interactions, relieving aos repression by Cic.
Differential Effects of Wild-Type and Mutant ATXN1 on CIC Transcriptional Repression
Having established that mutant ATXN1 interferes with the function of Cic as a repressor in Drosophila, we asked whether ATXN1 affects the function of CIC in a mammalian system. We performed luciferase assays using a reporter construct bearing six copies of the recently identified CIC binding site (CBS) (Kawamura-Saito et al., 2006). We observed a moderate decrease in luciferase activity when HEK293T cells were transfected with a small amount (2.5 ng) of CIC-S, whereas coexpression with ATXN1[2Q] decreased luciferase activity 2-fold ( Figure 7 ). The synergistic effect of ATXN1 and CIC-S coexpression on the transcriptional repression activity of CIC-S required the AXH domain. Interestingly, the ability of ATXN1[82Q] to repress transcription was impaired in comparison with ATXN1[2Q] only when CIC-S was cotransfected (Figure 7 ). These data demonstrate a direct link between the transcriptional repression activities of CIC and ATXN1 and show that polyglutamine expansion alters functions that depend on the interaction of these proteins.
DISCUSSION
The data presented in this study demonstrate that the majority of cerebellar ATXN1 associates into a group of large complexes that contain the transcriptional repressor CIC. We found that a nonpathogenic form of polyglutamineexpanded ATXN1, the S776A mutant, does not associate with the large ATXN1-CIC complexes, indicating that incorporation of polyglutamine-expanded ATXN1 into these complexes is important for its toxicity. Our findings that the majority of endogenous CIC associates with ATXN1 and that CIC levels are decreased in the absence of ATXN1 underscore the functional relationship between these two proteins. Lastly, we demonstrate that polyglutamine-expanded ATXN1 alters the repressor activity of CIC in vitro and in vivo. We conclude that ATXN1 acts in a transcriptional repressor complex and that polyglutamine-expanded ATXN1 exerts neurotoxicity through its native complexes containing CIC rather than through aberrant interactions with novel proteins. The complementary approaches we have taken permitted us to go beyond the identification of binary protein-protein interactions and to elucidate pathologically relevant alterations in native protein complexes harboring the disease protein.
Previous work from our lab and others has identified several ATXN1-interacting proteins and genetic modifiers of SCA1 phenotypes that are involved in transcriptional regulation, including silencing mediator of retinoid and thyroid hormone receptors (SMRT), polyglutamine binding protein 1 (PQBP1), and growth factor independent-1 (Gfi-1) (Fernandez-Funez et al., 2000; Okazawa et al., 2002; Tsai et al., 2004; Tsuda et al., 2005) . It remains unknown, however, whether these proteins form stable complexes or transiently interact with ATXN1. For example, the interaction of ATXN1 with the Senseless/Gfi-1 proteins leads to their destabilization and is expected to be transient (Tsuda et al., 2005) . Consistent with this, we did not find mouse Gfi-1 or SMRT associated with the major ATXN1 complexes in vivo (data not shown).
CIC contains a Sox-like high mobility group (HMG) box and likely acts as a transcriptional repressor (Atkey et al., 2006; Jimenez et al., 2000; Roch et al., 2002) . Given that ATXN1 lacks sequence-specific DNA binding activity (de Chiara et al., 2005) , CIC could be involved in directing ATXN1 to gene targets for repression. Our studies clearly show that ATXN1 has a synergistic effect on the transcriptional repressor activity of CIC that is partially compromised by the polyglutamine expansion. One possible explanation is that polyglutamine expansion alters the conformational state of the ATXN1 protein, which in turn alters the conformational or functional state of the ATXN1-CIC complex. Identifying transcriptional targets of the ATXN1-CIC complexes, particularly in the selectively vulnerable Purkinje cells, will likely reveal specific pathways that are critical for disease pathogenesis.
Our findings for SCA1 may apply to other polyglutamine diseases. Indeed, altered interactions of mutant Huntingtin with HAP1 and p150
Glued have been associated with impaired axonal trafficking of BDNF (Gauthier et al., 2004) . Thus, changes in native complexes could be one of the final steps of commonality in polyglutamine disease pathogenesis. Beyond this step, we suggest that the features particular to each disease are determined by both transient and stable protein interactions and the susceptibility of such interactions to conformational or functional alterations by the soluble polyglutamine-expanded disease protein. Determining how polyglutamine expansion alters the activity of the disease protein could enable therapeutic approaches to counter neuropathology by either blocking specific interactions that mediate selective neurotoxicity or modulating the downstream events of such interactions. Beyond polyglutamine diseases, it is becoming clear that elevated levels of even wild-type amyloid precursor protein and wild-type a-synuclein cause dementia and Parkison disease, respectively, just as overexpression of wild-type ATXN1 produces neurodegeneration (Eriksen et al., 2005; Fernandez-Funez et al., 2000; Rovelet-Lecrux et al., 2006) . Identifying these native protein complexes could point to key effectors or modifiers of the disease phenotypes. HEK293T cells transfected with a luciferase reporter that has CIC binding sites and expression plasmids (CIC-S and ATXN1 variants) in duplicate. The luciferase data are expressed as mean percentage of luciferase activity (± standard error) relative to the reporter alone (n R 4, t test * p < 0.05 and ** p < 0.005).
EXPERIMENTAL PROCEDURES
Column Fractionation and Analysis Chromatography was carried out at 4 C using the Amersham Pharmacia LCC-500 FPLC system. Unless stated otherwise, the data shown represent >10 independent runs for each genotype analyzed. Cerebellar extracts were prepared fresh by dounce homogenization of one to two cerebella from age-matched mice (%16 weeks) dissected in TST buffer (50mM Tris, pH 8, 75mM NaCl, 0.5% Triton X-100, 1mM PMSF, and protease inhibitors). Seven hundred microliters were loaded for FPLC. Gel filtration was a Superose 6 10/300 GL column (Amersham Pharmacia) equilibrated in buffer (50 mM Tris, pH 8, 20mM NaCl) at 0.4 ml/min. Fractions were collected every 0.5 ml or 1 ml volume, column void volume was 7.7ml, and elution volumes of gel-filtration standards were 12.4 ml for thyroglobulin (669 kDa), 15.8 ml for ADH (150 kDa), and 19.2ml for cytochrome C (12.4 kDa). Anion exchange was a MonoQ 5/5 HR column (Amersham Pharmacia) equilibrated in buffer (50 mM Tris, pH 8, 50 mM NaCl); after washing the column with $13 column volumes of the same buffer, bound proteins were eluted by a 20 ml linear NaCl salt gradient from 50 mM to 600 mM NaCl in 50 mM Tris, pH 8 at 1ml/min; 1 ml fractions were collected. All fractions were supplemented with protease inhibitors and immediately prepared for SDS-PAGE.
Immunoprecipitation Protein (0.5 mg) from cerebellar extracts in 200 ml TST buffer were diluted with 800 ml of cold PBS (Input). Two microliters of Anti-ATXN1 (11NQ) serum or preimmune serum was added and incubated overnight at 4 C. IP was performed with BSA-blocked protein G sepharose beads, and the immunodepleted supernatant (Post-IP Supernatant) was saved, and the pellet (IP pellet) was resuspended in sample buffer following three to six washes with cold PBS. Input, post-IP supernatant, and IP pellets were analyzed by SDS-PAGE and western blot.
RNA and Protein Analyses
RNA isolation and northern blot was as described (Emamian et al., 2003) . The Gapdh probe is a 486 bp PCR fragment of the mouse cDNA; the Cic probe is a 530 bp SpeI fragment of the coding region common to both isoforms, and the Sca1 probe is as clone corresponding to mouse cDNA. Guinea pig polyclonal anti-CIC serum was generated by immunizing with bacterially expressed HIS-tagged C-terminal 214 amino acids of CIC (Cocalico). Mouse monoclonal anti-FLAG M2 (Sigma), rabbit polyclonal anti-ATXN1 (11750VII and 11NQ), mouse monoclonal anti-GAPDH (Advance Immunochemical), and rabbit polyclonal anti-AKT (Cell Signaling) were used. SDS-PAGE western blotting and immunohistochemistry followed standard protocols (Chen et al., 2003; Watase et al., 2002) . Yeast two-hybrid assay was performed as previously described (Lim et al., 2006) .
Fly Strains
Drosophila cic cDNA was inserted in the pUAST vector to generate UAS-cic transgenic lines. Other strains used were UAS-SCA1[82Q] (F7, N35Y, M6) (Fernandez-Funez et al., 2000) , UAS-SCA11[82Q]DAXH (Tsuda et al., 2005) , C5-GAL4 (Yeh et al., 1995) , UAS-GFP (H. Bellen), cic 2 (Roch et al., 2002) , aos
W11
, and yw (Bloomington stock center).
X-Gal Staining and SEM Thirty-six hour APF pupae were fixed in 0.3% glutaraldehyde solution for 10 min. The pupal wings were dissected in 1XPBS and washed in 1XPBS for 15-30 min before staining in 0.3% X-gal in Fe/NaP solution for 3 hr at 37 C. Processing of Drosophila for SEM was performed as previously described (Fernandez-Funez et al., 2000) . Image acquisition was taken from MD Anderson SEM core.
Luciferase Assay
Cotransfected were 1.8 3 10 5 HEK293T cells in 24-well plates using Lipofectamine 2000 (Invitrogen) with 50 ng of the pGL3-Promoter (Promega) containing six copies of CIC binding sites (TGAATGAA or TGAATGGA) (Kawamura-Saito et al., 2006) , 10 ng of pRL-TK, and 2.5 ng of expression plasmids as indicated. The total amount of DNA transfected was kept constant by adding pcDNA3.1(À) (Invitrogen). Luciferase activities were measured using the dual luciferase reporter assay system (Promega). 
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